ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the ...

“This is the second study in the past three months to show that TAC-STIM provided a clear improvement in the ability of America’s warfighter to learn a critical skill. We look forward ...

Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024 Revenue excluding TAC-STIM totaled $6.6 million, reflecting 29% year-over-year growth Announced the ...

TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STIM is a portable, easy-to-use tool that leverages electroCore's patented technology ...

“This is the second study in the past three months to show that TAC-STIM provided a clear improvement in the ability of America’s warfighter to learn a critical skill. We look forward to the ...

ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf ...